Bristol Adds Diabetes Class Warning To Abilify Labeling; “Paucity” Of Reports Cited For Antipsychotic

Bristol and Otsuka had been seeking to persuade FDA that the atypical antipsychotic should be exempt from a class-wide hyperglycemia warning. Bristol will continue discussions with the agency as new data become available.